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Treatment of Iron-deficiency Anemia in Patients with Subclinical 
Hypothyroidism 
BACKGROUND 
 Subclinical hypothyroidism is associated with hypercholesterolemia, infertility, iron-deficiency 
anemia, and poor obstetric outcome.  
 Recent studies have shown an association between iron-deficiency anemia and subclinical 
hypothyroidism, and treatment with levothyroxine can improve the response to iron salt.   
 No prior studies have studied a combination of levothyroxine and iron salt in patients with iron-
deficiency anemia and subclinical hypothyroidism as compared to each agent as monotherapy. 
OBJECTIVE 
 To determine whether treatment of subclinical hypothyroidism and iron-deficiency anemia with 
a combination of levothyroxine and iron salt would be superior to each treatment as 
monotherapy. 
METHODS 
 Design: Single-center, double-blinded, randomized, active-controlled, parallel experimental trial. 
The length of the trial was 3 months. 
 Inclusion criteria: New diagnosis of subclinical hypothyroidism (defined as TSH between 4.5-10 
and normal free T4 and T3) and iron-deficiency anemia (Hgb < 12 g/dL  and ferritin < 25 µg/L for 
women; Hgb < 13.5 g/dL and ferritin < 30 µg/L for men). 
 Exclusion criteria: Females with a menstrual period lasting more than 5 days or more than usual 
amount of bleeding; patients with genitourinary or GI blood loss; hemolytic anemia; prior 
thyroid, cardiovascular, respiratory, renal, and liver disease; any chronic diseases, including 
diabetes, uncontrolled HTN, adrenal insufficiency, other endocrine disorders; or any cause for 
anemia other than iron deficiency and subclinical hypothyroidism. 
 60 patients enrolled, 20 in each of 3 groups: 
o Ferrous sulfate 65 mg/day + matching placebo 
o Levothyroxine 50 mcg/day + matching placebo 
o Ferrous sulfate 65 mg/day + levothyroxine 50 mcg/day 
 Primary outcome measure: Change from baseline in hemoglobin 
 Secondary outcome measures: Change from baseline in serum ferritin and TSH 
 Power was not calculated in the study. 
 Per-protocol data-handling method employed. 
RESULTS 
 For the primary outcome measure, the change in hemoglobin from baseline in g/dL, the iron 
group increased 0.005 ± 0.39, levothyroxine 0.26 ± 0.675, and iron + levothyroxine increased 
1.17 ± 0.59, p<0.0001 for iron and levothyroxine versus either treatment alone. 
 For the secondary outcome measure, change in ferritin from baseline in ng/mL, iron group 
increased 0.722 ± 5.32, levothyroxine 0.61 ± 3.77, and iron + levothyroxine 10.78 ± 5.19, , 
p<0.0001 for iron and levothyroxine versus either treatment alone. 
 For change in TSH, iron decreased TSH 0.580 ± 1.67, levothyroxine 5.75 ± 1.4, and iron + 
levothyroxine 5.12 ± 2.25. Both groups containing levothyroxine significantly decreased TSH 
compared to iron alone (p<0.0001), and there was no statistical difference between the two 
levothyroxine-containing groups. 
 For the before-and-after treatment parameters within each group, the only significant changes 
were TSH decrease in levothyroxine, and Hgb and ferritin increase and TSH decrease with iron + 
levothyroxine, all with p<0.001. 
 The authors suggest a regimen of levothyroxine + iron salt in patients with coexisting subclinical 
hypothyroidism and iron-deficiency anemia. 
 
STRENGTHS 
 Double-blind, randomized, active-controlled, parallel study design 
 No apparent bias 
LIMITATIONS 
 Low dosages of drugs employed 
 No adverse event reporting 
 Short duration of study 
 Unclear recruitment techniques 
CONCLUSIONS 
 Currently, enough evidence exists to recommend that patients with iron deficiency anemia who 
do not respond to iron therapy should have other causes investigated, including subclinical 
hypothyroidism.  In patients with both iron-deficiency anemia and subclinical hypothyroidism, it 
is reasonable to treat patients with both iron supplementation and levothyroxine. 
 Further studies are needed to clarify the relationship between iron-deficiency anemia and 
thyroid function.  Studies should be larger, longer in duration, multicenter, and take 
comorbidities into account. It’s important to also take adverse events into consideration. In 
addition, Iron doses should be higher and levothyroxine dose titration should also be 
incorporated. 
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